IL2 and type 1 diabetes mellitus: In a polyclonal Treg therapy trial, Marek-Trzonkowska et al. showed that infusing up to 2 doses of Tregs at 30 × 106/kg in young individuals led to a decrease of IL-2 in the serum of T1D patients after Treg infusion (46).